Presently, it is not recommended to routinely employ immunohistochemical staining for the p53 tumor suppressor gene, polymerase chain reaction analysis of tumor DNA for K-ras gene mutations, and the addition of flow cytometry to assess aneuploidy for prognosis determination and/or prediction of treatment response. This evidence concerns the gene KRAS and neoplasm.